Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risankizumab + trosunilimab
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ABBV-466 is an investigational, dual-targeting fixed-dose combination therapy developed by AbbVie for the treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. It combines risankizumab, a humanized monoclonal antibody that selectively inhibits the p19 subunit of interleukin-23 (IL-23), with trosunilimab (ABBV-382), a humanized monoclonal antibody that targets the alpha-4 beta-7 (α4β7) integrin. By simultaneously blocking IL-23-mediated inflammatory signaling and inhibiting α4β7-mediated trafficking of immune cells to the gut, ABBV-466 is designed to achieve deeper and more sustained disease control than either monotherapy alone. The combination is currently being evaluated in Phase 2 clinical trials.
- Other names
- ABBV 466ABBV466ABBV-466risankizumab + ABBV-382risankizumab/ABBV-382risankizumab/trosunilimabSkyrizi + ABBV-382
02
Targets
ITGA4 (Integrin alpha-4)ITGB7 (Integrin beta-7)IL23A (Interleukin-23 p19 Subunit)
Beyond the preview
Go deeper on risankizumab + trosunilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risankizumab + trosunilimab.